(Q39712673)

English

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.

scientific article published on 20 April 2010

Statements

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. (English)
Jonathan M Levitt
Hideyuki Yamashita
Weiguo Jian
Seth P Lerner
Guru Sonpavde
20 April 2010
1128-1135

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit